Skip to Content

Join the 'Maraviroc' group to help and get support from people like you.

Maraviroc News

ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living With HIV

Posted 17 Nov 2016 by Drugs.com

Research Triangle Park, NC — On November 4, 2016, ViiV Healthcare received approval from the U.S. Food and Drug Administration (FDA) to market Selzentry for the treatment of only CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents, in pediatric patients 2 years of age or older who weigh at least 10 kilograms (kg).[1] Selzentry is a first-in-class CCR5 co-receptor antagonist designed to inhibit entry into the immune system’s CD4+ T-cells by CCR5-tropic HIV-1. Selzentry is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. In addition to the 150 milligram (mg) and 300 mg Selzentry tablets currently available, new 25 mg and 75 mg tablets and a 20 mg per milliliter (mL)oral solution will be available in January 2017. The dose of Selzentry in pediatric patients 2 years of age and older should be based on the patient’s body weight and the drug inter ... Read more

Related support groups: HIV Infection, Selzentry, Maraviroc

HIV Can Persist in Body Despite Drug Therapy

Posted 27 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – Even when blood tests of HIV patients on antiretroviral drugs show no sign of the AIDS-causing virus, it can still be replicating in lymphoid tissue, researchers report. The study offers important new insight into how HIV persists in the body despite treatment with the powerful drugs, according to the team of international researchers led by Northwestern University's Feinberg School of Medicine in Chicago. To reach their finding, they examined viral sequences in samples of lymph node and blood cells from three HIV-infected patients who had no detectable virus in their blood. And what they found was that a viral reservoir in lymphoid tissue, which scientists believed held long-lived infected cells in a resting state, was being constantly replenished with infected cells. "The challenge is to deliver drugs at clinically effective concentrations to where the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Complera, Triumeq, Baraclude, Victrelis, Genvoya, Sofosbuvir, Viread, Kaletra, Viekira Pak, Entecavir, Tenofovir, Diagnosis and Investigation

HIV Therapy May Also Lower Risk for Hepatitis B, Study Says

Posted 12 Oct 2015 by Drugs.com

MONDAY, Oct. 12, 2015 – Not only does effective HIV therapy thwart the AIDS-causing virus, it may also reduce the risk for hepatitis B infection, a new study says. "What this means to us is that effective HIV therapy appears to restore an impairment in the immune response that protects someone with HIV from acquiring hepatitis B infection," study senior author Dr. Chloe Thio, a professor of medicine at Johns Hopkins University School of Medicine, said in a university news release. The study, published in the October issue of Annals of Internal Medicine, involved 2,400 gay and bisexual men who were enrolled in the Multicenter AIDS Cohort Study. Researchers found that the men successfully treated with HIV therapy had the same risk for hepatitis B infection as the men who did not have HIV. Hepatitis B is a virus that can damage the liver. The study showed HIV-positive men on HIV therapy ... Read more

Related support groups: Harvoni, HIV Infection, Valtrex, Acyclovir, Atripla, Hepatitis B, Ribavirin, Sovaldi, Valacyclovir, Pre-Exposure Prophylaxis, Incivek, Zovirax, Pegasys, Truvada, Stribild, Triumeq, Complera, Baraclude, Victrelis, Famciclovir

Almost Half of American Adults With HIV Don't Take Meds: Report

Posted 24 Sep 2015 by Drugs.com

THURSDAY, Sept. 24, 2015 – Almost half of American adults infected with HIV don't take medications that can prevent them from developing AIDS, a new government report shows. The statistics, based on data gathered from 2007 to 2012, are a few years out of date, so it's not clear whether the situation has changed. Still, the report – an analysis of people aged 18 to 59 – suggests a widespread lack of recommended care. "Based on what we know nowadays, everyone who's HIV-positive should be on therapy," said Dr. Carlos del Rio, co-director of the Center for AIDS Research at Emory University, in Atlanta. "This highlights the challenges we have ahead because we have such an unequal epidemic." The report, authored by Dr. Joseph Woodring of the U.S. National Center for Health Statistics, estimated the prevalence of HIV infection based on a survey of more than 10,000 people. The survey found ... Read more

Related support groups: HIV Infection, Tamiflu, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Sofosbuvir, Viread, Kaletra, Oseltamivir, Norvir, Entecavir, Tenofovir, Telaprevir, Boceprevir, Prezista, Reyataz, Lamivudine, Nevirapine

HIV Drug May Prevent Bone Marrow Transplant Complication

Posted 11 Jul 2012 by Drugs.com

WEDNESDAY, July 11 – An HIV drug significantly reduced the risk of graft-versus-host disease, an all-too-common complication in blood cancer patients following bone marrow transplants, new research finds. Bone marrow is the spongy tissue inside the bones that contains immature cells, or stem cells. In an "allogeneic" bone marrow transplantation, also called a stem cell transplant, a patient's own stem cells and immune system are wiped out by chemotherapy and radiation. Then, the patient receives the transplant, or bone marrow, from a closely matched donor. The treatment is used for several types of blood cancers, including lymphoma and leukemia. But a common complication of a bone marrow transplant is graft-versus-host disease. It occurs when transplanted immune cells attack patients' healthy tissue, a complication that can be minor or life-threatening. "Graft-versus-host disease ... Read more

Related support groups: Graft-versus-host disease, Maraviroc, Selzentry

Anti-HIV Drugs May Help Prevent Spread of Virus

Posted 27 May 2010 by Drugs.com

THURSDAY, May 27 – People who are HIV-positive can lower their risk for transmitting the virus to their partners by 90 percent by taking antiretroviral drugs, new research has found. Antiretroviral drug therapy helps reduce HIV levels in the infected person's blood, which in turn makes the person less infectious to others. The drugs are commonly taken in the United States by people with HIV, the virus that causes AIDS. In the new research, published online May 26 in The Lancet, investigators studied more than 3,400 heterosexual couples in seven African countries. In each couple, one person was infected with HIV and the other was not. No one in the study was taking antiretroviral drugs. Health workers counseled the couples about preventing HIV transmission and followed up with them for two years. During that time, periodic blood tests measured HIV levels in the blood, and people were ... Read more

Related support groups: HIV Infection, Atripla, Truvada, Baraclude, Viread, Kaletra, Tenofovir, Entecavir, Norvir, Nevirapine, Reyataz, Lamivudine, Combivir, Prezista, Abacavir, Ritonavir, Lexiva, Norvir Soft Gelatin, Epivir, Interferon Alfa-2B/Ribavirin

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection

Related Drug Support Groups

Selzentry

Maraviroc Patient Information at Drugs.com